{"brief_title": "Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine", "brief_summary": "The purpose of this phase II, randomized, open-label clinical trial is to study 2 schedules of single-agent Irinotecan in women with metastatic breast cancer who have experienced failure of prior therapy with an anthracycline, a taxane, and capecitabine. Patients will receive Irinotecan capsules either once each day for 5 days, or once a day for 14 days in 3 week cycles.", "condition": "Breast Neoplasms", "intervention_type": "Drug", "intervention_name": "Irinotecan", "criteria": "Inclusion Criteria: - Women with diagnosis of primary adenocarcinoma of the breast - Presence of locally advanced or metastatic disease non-amenable to surgery or radiation therapy with curative intent - At least one measurable lesion >20mm (or >10 mm with spiral CT scan) - Must have received (and failed) prior treatment with an anthracycline, a taxane, and capecitabine in the adjuvant and/or advanced disease treatment setting - Women at least 18 years old, with performance status 0-2 Exclusion Criteria: - Prior treatment with another topoisomerase I inhibitor - Current enrollment in another clinical trial", "gender": "Female", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00072852.xml"}